- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Yoon on Updated Results of the KEYNOTE-061 Study in Advanced Gastric/GEJ Cancer
July 2nd 2020, 10:00pm
ESMO Gastrointestinal Cancers Congress
Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.
Irinotecan Monotherapy Shows Similar Activity, Improved Safety as Chemo Combo in Advanced Gallbladder Cancer
July 2nd 2020, 9:00pm
ESMO Gastrointestinal Cancers Congress
Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.
Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder Cancer
July 2nd 2020, 6:24pm
ESMO Gastrointestinal Cancers Congress
Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.
Infigratinib Under Investigation in FGFR2-Altered Advanced Cholangiocarcinoma
July 2nd 2020, 6:15pm
ESMO Gastrointestinal Cancers Congress
Ghassan K. Abou-Alfa, MD, discusses the design and aim of the PROOF trial in advanced cholangiocarcinoma.
Dr. Abou-Alfa on Key Eligibility Criteria for the PROOF Trial in Cholangiocarcinoma
July 2nd 2020, 5:50pm
ESMO Gastrointestinal Cancers Congress
Ghassan K. Abou-Alfa, MD, discusses key eligibility criteria for the phase 3 PROOF trial in cholangiocarcinoma.
Maintenance Olaparib Maintains Benefit in Metastatic Pancreatic Cancer, Regardless of Age
July 2nd 2020, 2:45pm
ESMO Gastrointestinal Cancers Congress
The safety and efficacy of maintenance olaparib in patients with BRCA1/2-mutated metastatic pancreatic cancer proved to be consistent irrespective of age, according to results of a subgroup analysis from the pivotal phase 3 POLO trial.
Real-World Data Indicate Favorable Efficacy With Nivolumab in Advanced Gastric Cancer
July 2nd 2020, 2:18pm
ESMO Gastrointestinal Cancers Congress
Yu Sunakawa, MD, PhD, further discusses the early real-world data from the DELIVER trial with nivolumab in patients with gastric/GEJ cancer and provided insight into what future analyses will examine.
Efficacy With Entrectinib in NTRK+ GI Cancers Indicates a Need for More Molecular Testing
July 1st 2020, 10:42pm
ESMO Gastrointestinal Cancers Congress
Manish R. Patel, DO, further discusses next steps for entrectinib, as well as the need for genetic testing to identify uncommon gene rearrangements in GI malignancies.
Durvalumab/Tremelimumab Combo Could Expand Frontline Options in Advanced HCC
July 1st 2020, 9:29pm
ESMO Gastrointestinal Cancers Congress
Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from a study of combination durvalumab and tremelimumab, as well as the clinical need for alternative combination regimens in advanced hepatcellular carcinoma.
Frontline NALIRIFOX Regimen Shows Promising Activity, Tolerability in Pancreatic Cancer
July 1st 2020, 8:57pm
ESMO Gastrointestinal Cancers Congress
The regimen of liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin demonstrated a tolerable safety profile with promising antitumor activity when used as frontline treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Atezolizumab/Bevacizumab Shows Comparable Activity in Older Patients With Advanced HCC
July 1st 2020, 6:24pm
ESMO Gastrointestinal Cancers Congress
The combination of atezolizumab and bevacizumab demonstrated comparable clinical activity and safety versus sorafenib in older and younger patients with previously untreated, unresectable hepatocellular carcinoma.
Dr. Patel on the Role of Entrectinib in Gastrointestinal Malignancies
July 1st 2020, 6:21pm
ESMO Gastrointestinal Cancers Congress
Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.
Nivolumab Demonstrates Survival and Safety Benefit in Frontline HCC With Longer Follow-Up
July 1st 2020, 5:24pm
ESMO Gastrointestinal Cancers Congress
Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from the long-term analysis of the CheckMate-459 trial in advanced hepatocellular carcinoma.
Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCC
July 1st 2020, 4:30pm
ESMO Gastrointestinal Cancers Congress
Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.
Liu Lends Insight on Highlights From ASCO 2020 in Lung Cancer
June 25th 2020, 4:02pm
A number of influential clinical trials were presented during the 2020 ASCO Virtual Scientific Program, 8 of which Stephen Liu, MD, discusses in depth in a virtual presentation during the 2020 ASCO Direct Highlights webcast.
Dr. Janjigian on Updated Results from the DESTINY-Gastric01 Trial in HER2+ Gastric Cancer
June 25th 2020, 3:10pm
Yelena Y. Janjigian, MD, discusses updated results from the phase 2 DESTINY-Gastric01 trial in previously treated patients with HER2-positive gastric cancer.
Dr. Usmani on Current Challenges in High-Risk Multiple Myeloma
June 25th 2020, 2:10pm
Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.
Dr. Ghosh on Efficacy Results from the Phase 2 PILOT trial in Non-Hodgkin Lymphoma
June 25th 2020, 1:15pm
Nilanjan Ghosh, MD, PhD, discusses efficacy results from the phase 2 PILOT trial in patients with high-risk relapsed/refractory B-cell non-Hodgkin lymphoma.
Dr. Moyers on Real-World Data With Adjuvant Immunotherapy in Melanoma
June 24th 2020, 9:45pm
Justin Moyers, MD, discusses real-world data and sociodemographic factors from an early analysis of the National Cancer Database associated with the treatment of adjuvant immunotherapy in stage III melanoma.
Double PIK3CA Mutations in Breast Cancer Increase Sensitivity to PI3Kα Inhibition
June 24th 2020, 8:27pm
Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.